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Transient Receptor Potential (TRP) channels modulate intracellular Ca2+ concentrations,
controlling critical cytosolic and nuclear events that are involved in the initiation and
progression of cancer. It is not, therefore, surprising that the expression of some TRP
channels is altered during tumor growth and metastasis. Cell migration of both epithelial
and endothelial cells is an essential step of the so-called metastatic cascade that leads
to the spread of the disease within the body. It is in fact required for both tumor
vascularization as well as for tumor cell invasion into adjacent tissues and intravasation
into blood/lymphatic vessels. Studies from the last 15 years have unequivocally shown that
the ion channles and the transport proteins also play important roles in cell migration. On
the other hand, recent literature underlies a critical role for TRP channels in the migration
process both in cancer cells as well as in tumor vascularization. This will be the main focus
of our review. We will provide an overview of recent advances in this field describing
TRP channels contribution to the vascular and cancer cell migration process, and we will
systematically discuss relevant molecular mechanism involved.
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INTRODUCTION
Metastasis is the main cause of mortality in cancer and depends
on two key processes: cell migration of cancer cell to invade
adjacent tissues followed by intravasation into blood/lymphatic
vessels and tumor vascularization, which give access to blood-
stream. During the metastatic process cell migration of both
epithelial and endothelial cells (EC) is an essential step lead-
ing to the spread of the primary tumor and to the invasion
of neighboring connective tissue, lymphatic system and blood
vessels. Cell migration and tumor vascularization are often
accompanied by changes in ion channel expression and/or activ-
ity and, consequently, by abnormal progression of the cellu-
lar responses with which they are involved. In particular Ca2+
channels are of utmost importance since Ca2+ is the key mes-
senger regulating signaling pathways important in cellular pro-
cesses as proliferation, apoptosis, gene transcription, migration
and angiogenesis (Roderick and Cook, 2008; Monteith et al.,
2012).
In this context the relatively recent Ca2+ channel family of
Transient Receptor Potential (TRP) have been associated with
several cancers and their role has been increasingly clarified the
two last decades (Bödding, 2007; Nilius et al., 2007; Gkika and
Prevarskaya, 2009; Prevarskaya et al., 2011). TRP proteins dis-
play an extraordinary diversity of functional properties and have
profound effects on a variety of physiological and pathologi-
cal conditions (Ramsey et al., 2006; Nilius et al., 2007; Montell,
2011). Indeed TRP channels modulate intracellular Ca2+ con-
centrations, controlling critical cytosolic and nuclear events that
are involved in the initiation and progression of cancer. It is not
therefore surprising that the expression and function of some
TRP channels is altered during tumor growth and metastasis. In
particular, a typical feature of TRP channels is their ability to
be activated by a wide range of external stimuli (including light,
sound, chemicals, temperature, and touch) as well as of changes in
the local environment (Venkatachalam and Montell, 2007; Nilius
and Owsianik, 2011). As such, they can be envisioned as poly-
modal molecular sensors suggesting that the physiologically rele-
vant stimulus for any given TRP will be governed by the specific
cellular context (i.e., phosphorylation status, lipid environment,
interacting proteins and concentration of relevant ligands), which
dramatically changes during carcinogenesis. Indeed, recent evi-
dences increasingly clarify the role for different TRP channels
making them very promising players since their expression and/or
activity mark and regulate specific stages of cancer progression
(Nilius et al., 2007; Gkika and Prevarskaya, 2011; Prevarskaya
et al., 2011; Ouadid-Ahidouch et al., 2013).
On the other hand, TRP channels are widely expressed in
ECs and their functions have been related to critical steps of
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tumor vascularization as well as in vivo angiogenesis (Fiorio Pla
et al., 2012a; Munaron et al., 2013). TRP channels-mediated Ca2+
influx can be triggered by the release from intracellular Ca2+
stores giving rise to store-operated Ca2+ entry (SOCE). An alter-
native route is second messenger, store-independent Ca2+ entry
(NSOCE) (Ambudkar and Ong, 2007).
Due to the essential role of cell migration of both epithelial and
EC in the so-called metastatic cascade that leads to the spread of
the disease within the body, we provide here an overview of recent
advances in this field describing TRP channels contribution to
migration process systematically discussing relevant molecular
mechanism involved.
TRPC CHANNELS
TRPC channels are tetrameric, non-selective cation channels,
which are central constituent of both store-operated Ca2+ entry
(SOCE) as well as receptor-activated Ca2+ entry (ROCE). TRPC
channels have been described to be functionally coupled to dif-
ferent tyrosine kinase receptor (i.e., VEGF, bFGF) and G protein-
coupled receptors (Ambudkar and Ong, 2007).
Increasing evidences show the involvement of these channels
in chemotaxis and directional migration processes (Schwab et al.,
2012).
TRPC1
The role of TRPC1 in cell migration has been shown by sev-
eral groups. In particular TRPC1 channels determine polarity
and persistence of different cell types and are involved in stimuli-
mediated directional cues in both in vivo and in vitro (Wang and
Poo, 2005; Fabian et al., 2008; Schwab et al., 2012).
As concerning cancer cell migration, TRPC1 is expressed in
several glioma cell lines, including D54, D65, GBM62, STTG1,
U87, and U251 and in Grade IV malignant glioma patient tis-
sue (Bomben and Sontheimer, 2008). In glioma cells TRPC1 has
been correlated with EGF-mediated directional migration. In par-
ticular EGF-mediated chemotactic migration is lost when TRPC
channels are inhibited pharmacologically and reduced when the
expression of TRPC1 is compromised through shRNA knock-
down. Interestingly, TRPC1 channels localize to the leading edge
of migrating glioma cells where they co-localize with mark-
ers of caveolar lipid rafts. This raft association appears impor-
tant since disruption of lipid rafts by depletion of cholesterol
impaired TRPC1channel-mediated Ca2+ entry and EGF medi-
ated chemotaxis (Bomben et al., 2011) (Table 1). Interestingly
TRPC1-mediated Ca2+ entry seems to colocalize with Chloride
Channel ClC-3 in caveolar lipid rafts of glioma cells. This inter-
action is functionally relevant during EGF-induced chemotaxis.
Therefore the authors propose that Cl− channels (most likely
ClC-3) are important downstream target of TRPC1 in glioma
cells, coupling elevations in [Ca2+]i to the shape and volume
changes associated with migrating cells (Cuddapah et al., 2013)
(Table 1; Figure 1).
Beside the described role on cancer cell migration, a proan-
giogenic role for TRPC1 has been described in vivo. Knockdown
of zebrafish TRPC1 by morpholinos causes severe angiogenic
defects in intersegmental vessel sprouting, presumably due to
impaired filopodia extension and EC migration. Furthermore,
in vivo time-lapse imaging of cellular behaviors showed that the
angiogenic defect caused by TRPC1 deficiency is associated with
markedly impaired filopodia extension, migration, and prolifer-
ation of intersegmental vessels (ISV) tip cells (Yu et al., 2010)
(Table 1). On the other hand TRPC1 is expressed in different
endothelial cell types, and promotes capillary-like tube forma-
tion in primary human umbilical vein EC (HUVEC) cells but not
on EA.hy926 cells, an endothelial cell line derived from HUVECs
fused with human lung adenocarcinoma cell line A549 (Antigny
et al., 2012) (Table 1).
Beside the role of resident (EC), great interest has been recently
focused on circulating endothelial progenitor cells (EPCs), a
subpopulation of bone marrow-derived mononuclear cells also
found in peripheral blood as important players in tumor vas-
cularization. They promote vessel formation in adult, and it
was recently reported that they have the ability to incorporate
into tumor tissues (Carmeliet, 2005; Bussolati et al., 2011). In
this regard, TRPC1 has been suggested to contribute to regula-
tion of cell migration of EPCs isolated from rats bone marrow.
Interestingly TRPC1 downregulation dramatically reduces SOCE
in EPC (Kuang et al., 2012) (Table 1). These data are in accor-
dance with data obtained from EPC isolated from peripheral
blood of patients affected by renal cellular carcinoma (RCC; RCC-
EPCs) and control EPCs (N-EPCs). In this study in fact Lodola
and co workers report that TRPC1 is upregulated in RCC-EPCs
where it’s involved in SOCE (Lodola et al., 2012). On the other
hand no data are at the moment available for a direct role for
TRPC1 in human EPC.
In conclusion, form the data available, TRPC1 seems to be a
general player involved in both cancer as well as endothelial cell
migration although the molecular mechanism is still elusive.
TRPC3
Not many data are available about the role of TRPC3 in cancer
cell or EC migration. However recently a functional expression
of TRPC3 has been described in MCF-7 breast cancer cell line.
TRPC3 mediates store-operated Ca2+ entry (SOCE) as shown
by TRPC3 knock down. Moreover PUFA (both arachidonic
acid (AA) and Lysophosphatidic Acid) inhibits TRPC3-mediated
Ca2+ entry, which correlates with inhibition of MCF-7 migra-
tion. The data suggest a possible role for TRPC3-mediated Ca2+
entry in breast cancer cell migration although a direct link is still
missing (Zhang et al., 2012) (Table 1).
TRPC5—TRPC6
TRPC6 was known till recently to increase proliferation of epithe-
lial cells in prostate (Thebault et al., 2006; Yue et al., 2009),
breast (Guilbert et al., 2008; Aydar et al., 2009), liver (El Boustany
et al., 2008) and renal cancer (Song et al., 2013). Since TRPC6
protein over expression in breast cancer is not correlated with
tumor grade, estrogen receptor expression or lymph node positive
tumors (Guilbert et al., 2008), one could think that TRPC6 plays
a role primarily in proliferation and not in metastasis. However,
two recent studies show that TRPC6 promotes cancer cell migra-
tion in head and neck squamous cell carcinomas (Bernaldo de
Quirós et al., 2013) and glioblastoma (Chigurupati et al., 2010).
In fact TRPC6 expression is increased in head and neck squamous
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Table 1 | TRP/Orai1 functions in cancer and endothelial cell migration.
Channel Cell type Cell migration Techniques used Proposed mechanism References
Epithelial Endothelial
TRPC1 Glioma cell lines;
zebrafish; HUVEC
+ + Boyden chamber;
morfolinos on
zebrafish;
tubulogenesis in vitro
EGF-mediated migration,
involvement of lipid raft, ClC-3
interaction/ filopodia extention
Yu et al., 2010; Bomben
et al., 2011; Antigny
et al., 2012; Cuddapah
et al., 2013
TRPC3 MCF-7 (breast
cancer)
+ ND Boyden chamber Indirect link Zhang et al., 2012
TRPC6 Head and neck
carcinoma cell line;
glioblastoma
multiple; HMEC;
HPAEC; HUVEC;
+ + Wound healing;
matrigel invasion
assays on transwell;
soft agar colonogenic
assay; tubulogenesis
in vitro
Notch activation under hypoxia
in turn promote TRPC6
expression; in EC PTEN
regulates TRPC6 expression
Hamdollah Zadeh et al.,
2008; Ge et al., 2009;
Chigurupati et al., 2010;
Kini et al., 2010; Bernaldo
de Quirós et al., 2013
TRPC5/
TRPC6
BAEC, MAEC ND − Wound healing Lysophosphatidylcholine
activate TRPC6 which in turn
promote TRPC5 membrane
expression
Chaudhuri et al., 2008
TRPV1 Human
hepatoblastoma
cells (HepG2);
cervical and bladder
cancer cell
± − Random cell
migration, boyden
chamber, matrigel
invasion assays, in
vivo xenografts on
nude mice
TRPV1 antagonist capsazepine
inhibits both
cannabidiol-induced tissue
inhibitors of the matrix
metalloproteinase 1 (TIMP-1)
expression and activation of
the MAPKs p38 and p42/44;
capsaicin promotes IGF
(insulin-like growth factor)-1
release, GZMA and MMP9
activation, a-tubulin
disassembly and cytoskeleton
degradation. The effect is
reverted by TRPV1
overexpression
Waning et al., 2007;
Ramer and Hinz, 2008;
Ramer et al., 2010;
Caprodossi et al., 2011
TRPV2 Prostate cancer
cells (PC3),
urothelial cancer
vells (T24/83)
+ ND Migration assays on
transwell, matrigel
invasion assays on
transwell, in vivo
xenografts on nude
mice
Lysophospholipids and
adrenomedullin activate TRPV2
via PI3K pathway. TRPV2
activation induce MMP2,
MMP9 and cathepsin B52
expression
Monet et al., 2010; Oulidi
et al., 2013
TRPV4 Hepatoblastoma cell
line (HepG2); bovine
capillary endothelial
(BCE) cells and
human dermal
microvascular
endothelial (HMVE);
BHMEC; TEC
+ + Random motility;
wound healing; live
cell microscopy after
mechanical shear
stress application
Ultrarapid activation by
b1integrin; activation by AA via
actin remodeling
Thodeti et al., 2009;
Matthews et al., 2010;
Fiorio Pla et al., 2012b
TRPM7 Breast cancer, lung
cancer,
nasopharingeal
cancer and
pancreatic ductal
adreno-
+ ND Matrigel invasion
assays on transwell
TRPM7 activation of Src-MAPK
signaling pathway, focal
adhesion number;
EGF-mediated TRPM7
membrane expression
Gao et al., 2011;
Middelbeek et al., 2012;
Meng et al., 2013
(Continued)
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Table 1 | Continued
Channel Cell type Cell migration Techniques used Proposed mechanism References
Epithelial Endothelial
TRPM8 Carcinoma
prostate
metastatic
cancer;
glioblastoma;
squamous
carcinoma cell
lines
− − Wound healing;
transwell; random
motility; in vivo
xenografts on nude
mice
Activation by icilin and PSA;
TRPM8 diminish PFAK levels
Wondergem et al., 2008;
Yang et al., 2009b; Gkika
et al., 2010; Zhu et al.,
2011; Okamoto et al.,
2012; Valero et al., 2012
ORAI1/
STIM1
Breast cancer;
cervical cancer;
HUVEC; EA.hy926
cells; EPC
+ + Transwell; matrigel
invasion assays on
transwell random
migration; in vivo
xenografts on nude
mice; in vitro
tubulogenesis; wound
healing
Stimulation of focal adhesion
turnover via ras and rac
GTPases; downstream to
VEGF.
Abdullaev et al., 2008;
Yang et al., 2009a; Chen
et al., 2011; Dragoni
et al., 2011; Li et al., 2011;
Beech, 2012
HMEC, human microvascular EC; HPAEC, human pulmonary artery EC; HUVEC, human umbilical vein EC; EA.hy926, EC line derived from HUVECs fused with
human lung adenocarcinoma cell line A549; BTEC, tumor derived EC from breast carcinoma; MAEC, Mause Aortic EC; BHMEC, brain microvascular EC; EPC,
endothelial precursors cells; RCC-EPC, EPC isolated from renal carcinoma patients; EGF, epithelial Growth Factor; ClC-3, chloride channel; PTEN, phosphatase and
tensin homolog protein; TIMP1, metallopeptidase inhibitor 1; MAPK, mitogen activated protein kinase; IGF, insulin-like growth factor; GZMA, Granzyme A; MMP9,
Matrix metalloproteinase 9; PI3K, Phosphatidylinositol 3-kinase; MMP2, Matrix metalloproteinase 2; AA, arachidonic acid.
cell carcinomas tumor samples and cancer cell lines. In this type
of carcinomas knockdown of TRPC6 expression does not signif-
icantly alter cell proliferation but dramatically inhibits invasion
(Bernaldo de Quirós et al., 2013). The authors showed by the
means of wound-healing assays and matrigel invasion assays that
the effect on invasion is much more pronounced than in migra-
tion: knock down of TRPC6 expression by siRNA resulted in a
36% decrease in cell migration and in a ∼90% decrease in inva-
siveness. These data suggest an essential role of TRPC6 in the 3D
motility of cancer cells (Bernaldo de Quirós et al., 2013). On the
other hand, in glioblastoma multiforme, the most common pri-
mary brain tumor in humans and one of the most angiogenic
tumors, TRPC6 expression is markedly upregulated compared to
normal brain tissue. This increase in the channel expression is
dependent on Notch activation under hypoxia conditions. Both
pharmacological inhibition of Notch and knockdown of TRPC6
expression reduce in a similar way glioma migration and invasion
in vitro (Chigurupati et al., 2010) (Table 1).
Beside its role on cancer cell migration, inhibition of the
hypoxia-induced TRPC6 expression has an effect in endothe-
lial cell tube formation in vitro as it reduced the number of
branch points (Chigurupati et al., 2010), indicating that TRPC6
is essential for the angiogenic potential of glioma cells. In this
regard, TRPC6 has been now largely accepted as a key player in
cell migration in both macrovascular as well as microvascular
EC. In particular it has been related to VEGF signaling pathway
as the responsible for Ca2+ influx and consequent downstream
effects (Cheng et al., 2006; Ge et al., 2009). Dominant negative
TRPC6 significantly reduces EC number, migration and sprout-
ing (Hamdollah Zadeh et al., 2008). Moreover, TRPC6 promotes
both proliferation and tubulogenesis induced by VEGF, but not
bFGF, in HUVECs (Ge et al., 2009). Phosphatase and tensin
homolog (PTEN) interacts with TRPC6 and regulates cell surface
expression of TRPC6 and consequently Ca2+ entry, endothe-
lial permeability, and in vitro angiogenesis in human pulmonary
arterial ECs (HPAECs) (Kini et al., 2010) (Table 1; Figure 1).
Interestingly PTEN-TRPC6-mediated migration and tubule for-
mation in vitro does not require the PTEN phosphatase domain,
pointing out an interesting new role for PTEN as scaffolding
protein (Kini et al., 2010).
Interestingly, TRPC6 can also inhibit EC migration acting
in concert with TRPC5: when ECs are incubated in lysophos-
phatidylcholine (LPC), rapid translocation of TRPC6 initiates
Ca2+ influx that results in externalization of TRPC5. Activation
of this TRPC6–5 cascades cause a prolonged increase in intra-
cellular Ca2+ concentration (Ca2+i) that inhibits EC movement.
This effect is largely attenuated in EC harvested from aortas of
TRPC6-/- mice: although LPC caused a prolonged rise in Ca2+i
in wild-type EC, it had no effect on Ca2+i in TRPC6-deficient
ECs (Chaudhuri et al., 2008) (Table 1; Figure 1). Moreover LPC-
mediated TRPC6 and TRPC5 activation is mediated by tyrosine
phosphorylation. This is an interesting finding since fyn and src
tyrosine kinases have been described to regulates TRPC6 activity
in COS-7 cells (Hisatsune et al., 2004).
Thus the final role of TRPC6 channels on EC migration is
closely associated with cellular microdomains composition: when
associated with VEGF receptor TRPC6 may function as down-
stream player and activate EC migration; on the other hand
when localized in proximity with TRPC5, TRPC6-TRPC5 cascade
results in attenuation of EC migration (Figure 1).
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FIGURE 1 | Schematic representation of TRP and ORAI1 channels
molecular mechanisms involved in cancer cell and endothelial cell
migration. The mechanisms are presented in representative Cancer cells
and endothelial cells without any tissue specification. AA, arachidonic acid;
ClC-3, Chloride channel-3; EC, endothelial cells; ER, endoplasmic reticulum;
bFGF, basic Fibriblast Growth Factor; GZMA, Granzyme A; GPCR, G-protein
coupled receptor; IGF, insulin-like growth factor; LPL, lysophospholipids; LPC,
lysophosphatidylcholine; LPI, lysophosphatidylinositol; MAPK, mitogen
activated protein kinase; MMP, Matrix metalloproteinase; MMP2, Matrix
metalloproteinase 2; NFAT, Nuclear factor of activated T-cells; PI3K,
Phosphatidylinositol 3-kinase; PTEN, Phosphatase and tensin homolog; Pyk2,
Protein tyrosine kinase Pyk2; SK3, K + channel; TIMP1, metallopeptidase
inhibitor 1; VEGF, Vascular Endothelium Growth Factor; VEGFR, VEGF
Receptor.
TRPV CHANNELS
TRPV1
A growing set of recent evidence using the agonists and antago-
nists of TRPV1 channel suggest that this channel could be impli-
cated in themodulation ofmigration and invasion of several types
of cancer cells (Waning et al., 2007; Ramer and Hinz, 2008; Ramer
et al., 2010; Caprodossi et al., 2011). The most known agonist
of TRPV1 capsaicin (the main component in chili pepper) has
been shown to lead to an acceleration of human hepatoblastoma
cells (HepG2) pretreated with hepatocyte growth factor (HGF).
In contrast, HepG2 cells kept in the absence of HGF are not
accelerated by capsaicin while the TRPV1 antagonist capsazepine
prevents the stimulation of migration. Patch-clamp experiments
of the treated cells suggest that the sustained stimulation ofmigra-
tion by capsaicin is probably due to a sustained elevation of
TRPV1 channel activity (Waning et al., 2007) (Table 1). However,
three other studies propose an anti-migratory and anti-invasive
role for TRPV1 in lung, cervical and bladder cancer cell (Ramer
and Hinz, 2008; Ramer et al., 2010; Caprodossi et al., 2011). In
particular, in the two studies by Ramer et al., it is shown that the
TRPV1 antagonist capsazepine restores invasiveness of lung and
cervical cancel cell, the inhibition of which is due to cannabinoid
treatment. It has to be noted that cannabinoids were shown to
have an antitumorigenic role inhibiting cell metastasis and angio-
genesis (Portella et al., 2003; Blázquez et al., 2004) most likely due
to stimulation and consequent desensitization of TRPV1 chan-
nel (De Petrocellis et al., 2011). The molecular mechanism of this
anti-invasive effect was further studied and it was shown that the
TRPV1 antagonist capsazepine causes a significant suppression of
both cannabidiol-induced tissue inhibitors of the matrix metal-
loproteinase 1 (TIMP-1) expression and activation of the MAPKs
p38 and p42/44 (Ramer et al., 2010) (Figure 1).
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TRPV1-mediated inhibition of migration has been analyzed
more in detail in a recent study in bladder cancer (Caprodossi
et al., 2011) (Table 1; Figure 1). In this study two urothelial cell
lines were used, the low grade RT4 cells and the moderately dif-
ferentiated 5637 cells of a higher grade in which TRPV1 mRNA
and protein levels are dramatically reduced as compared with
RT4 cells. Capsaicin promotes the invasiveness of 5637 cells by
triggering IGF (insulin-like growth factor)-1 release, GZMA and
MMP9 activation, a-tubulin disassembly and cytoskeleton degra-
dation. Interestingly, TRPV1 transfection of these cells reverts
the capsaicin-induced migration and MMP9 activation, suggest-
ing an inhibitory role played by TRPV1 in urothelial cancer cell
invasion and metastasis.
TRPV2
TRPV2 is expressed in aggressive prostate and bladder cancer cells
and tissue samples in which its activation stimulates the migra-
tion and invasive phenotype of these cells (Caprodossi et al., 2008;
Monet et al., 2009, 2010). In particular two factors, lysophospho-
lipids and adrenomedullin, were shown to increase cell motil-
ity by activating the channel. Lysophospholipids are significant
actors in tumor development, since they stimulate angiogenesis,
growth, survival and migration of malignant cells from various
origins (Raj et al., 2004; Hao et al., 2007). Likewise lysophos-
pholipids (LPC and lysophosphatidylinositol, LPI) were shown
to act as new physiological stimuli for TRPV2 channel inducing
channel translocation to the plasma membrane through activa-
tion of Gi or Go proteins and phosphatidylinositol 3,4-kinase
(PI3,4K signaling). This accumulation of the TRPV2 channel in
the plasma membrane results into higher Ca2+ entry which in
turn promoted prostate cancer cell migration by induction of key
invasion markers, such as the matrix metalloproteinases MMP2,
MMP9 and cathepsin B52 (Monet et al., 2009). Further it was
shown that siRNA- mediated TRPV2 silencing reduces the size
and invasive properties of xenografted prostate tumors in nude
mice and downregulates the expression of MMP2, MMP9 and
cathepsin B52, suggesting that TRPV2 is a viable pro-metastatic
target in vivo (Monet et al., 2010) (Table 1; Figure 1).
The second factor characterized so far acting on cell migration
through TRPV2 is adrenomedullin, a peptide originally isolated
from a human pheochromocytoma (Kitamura et al., 1993). A
number of studies have implicated adrenomedullin in tumor
growth, progression and metastasis by affecting angiogenesis,
cell proliferation, apoptosis and migration (Zudaire et al., 2003;
Nakamura et al., 2006; Nikitenko et al., 2006). In this regard,
it was recently shown that adrenomedullin, induces prostate
and urothelial cancer cell migration and invasion through
TRPV2 translocation to plasma membrane and the subsequent
increase in resting Ca2+ level (Oulidi et al., 2013) (Table 1;
Figure 1).
TRPV4
TRPV4 is an interesting emerging player in cell migration. In par-
ticular, an increasing amount of literature is accumulating on vas-
cular EC: the high selectivity of the pharmacological compounds
acting as antagonists for this channel makes it a promising molec-
ular target for antiangiogenic treatments (Everaerts et al., 2010).
TRPV4 is widely expressed in the vascular endothelium where
it is proposed to act as a mechanosensor. The channel is indeed
activated by changes in cell morphology, during cell swelling and
shear stress (Vriens et al., 2004; Everaerts et al., 2010). In par-
ticular fluid shear stress regulates cell re-orientation in a TRPV4
dependent manner, while in larger arteries the channel is a key
player in shear stress-induced vasodilation (Hartmannsgruber
et al., 2007; Thodeti et al., 2009). More recently the molec-
ular mechanism underlie ultrafast TRPV4 by shear stress has
been investigated: mechanical force applied through b1 inte-
grin induces a near instantaneous and localized transient TRPV4
mediated Ca2+ influx in intact capillary EC expressing both
native and genetically engineered integrin receptors. The ultra
rapid response of the Ca2+ signal (within 4msec) observed using
whole cell Ca2+ imaging strongly suggests that TRPV4 chan-
nels are activated in the absence of second messengers, and are
directly mechanosensitive (Matthews et al., 2010). Both shear
stress and agonist-activation of TRPV4 enhance EC prolifera-
tion and trigger collateral growth after arterial occlusion (Troidl
et al., 2009). Fiorio Pla et al. recently demonstrated that AA-
activated TRPV4 is essential for breast tumor-derived EC (BTEC)
migration: the expression of endogenous TRPV4 was significantly
higher in BTEC compared to “normal” EC (HMEC) (Fiorio Pla
et al., 2012b). TRPV4 plays a key role in mediating Ca2+ entry in
BTEC as loss of TRPV4 expression resulted in complete inhibi-
tions of Ca2+i responses and migration induced by the specific
agonist phorbol ester 4α-phorbol 12,13-didecanoate (4αPDD)
and AA. Finally, AA induces actin remodeling and increases sur-
face expression of TRPV4 in BTEC (Fiorio Pla et al., 2012b)
(Table 1; Figure 1). It is important to stress the use of BTECs
in this study as suitable model to investigate the role of proan-
giogenic factors and their related cell signaling triggered in ECs,
compared to the widely used ECs obtained from normal tissues.
In fact the great amount of detailed studies on proangiogenic
endothelial signaling have been performed in vitro on different
types of primary or immortalized macrovascular and microvas-
cular EC lines from human or animal normal tissues; on the
other handmuch less information is available so far about tumor-
derived ECs (Fiorio Pla et al., 2012a). As previously reported for
TRPC6, the dynamics of a single TRP should be considered in a
more integrated framework: in this regard recent data reported
that the trafficking to the plasma membrane of TRPV4-TRPC1
heteromeric complex is enhanced by Ca2+ store depletion in
HUVEC, resulting in an enhanced Ca2+ influx upon exposure to
shear flow (Ma et al., 2010). Moreover, enhanced TRPV4-C1 traf-
ficking to the plasma membrane contribute to SOCE and ISOC
in the EC (Ma et al., 2011). On the other hand, after a heated
debate, it is now largely accepted thet TRPC1 channels contribute
to SOCE in different cells type including HUVECs (Cheng et al.,
2013).
As regarding cancer cells, not much is known about its role
in migration. However a study from Schwab and co-workers has
described a role for TRPV4 in hepatoblastoma cell line (HepG2):
4αPDD led predominantly to increased lamellipodial dynamics
and velocity in HGF treated HepG2 cells, although the displace-
ment, a measure of the cell persistence, was not statistically
different from control conditions (Waning et al., 2007).
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TRPM CHANNELS
TRPM1
TRPM1 has been suggested to be a tumor suppressor and a
decrease in TRPM1 expression appears to be a prognostic marker
for metastasis in patients with localized malignant melanoma
(Duncan et al., 1998; Fang and Setaluri, 2000). Taking in con-
sideration the loss of expression of TRPM1 channel during the
progression of melanomas toward more invasive forms it could
be hypothesized that TRPM1 presence and/or activation inhibits
migration. A very interesting recent study shed light to that issue
and the authors report that tumor suppressive activity is not
mediated by TRPM1 directly but by a microRNA (miR-211)
hosted within an intron of TRPM1. Increasing expression of miR-
211 but not TRPM1 reduces migration and invasion of malignant
and highly invasive human melanomas characterized by low lev-
els of melastatin andmiR-211. Thus this intronic miRNA assumes
a tumor suppressive function previously ascribed to trpm1, its
host gene (Levy et al., 2010). However, miRNA genes are fre-
quently hosted by protein coding genes, phenotypes attributed
to genetic deletion of protein-coding genes may actually be
attributable to abrogated expression of the hosted miRNAs
(Moffett and Novina, 2007). It has to be noted that a single
miRNA may target thousands of genes: it is therefore possible
that altered expression of a single miRNA can regulate complex
phenotypes. Indeed, a network analysis of melanoma-expressed
genes filtered for their roles in metastasis identified three cen-
tral node genes: IGF2R, TGFBR2, and NFAT5 (Levy et al., 2010).
Expression of these genes is reduced by miR-211 and knockdown
of each gene phenocopied the effects of increased miR-211 on
melanoma invasiveness. In conclusion, this study suggest miR-
211 as a suppressor of melanoma invasion whose expression is
silenced (or selected against) via suppression of the entire melas-
tatin locus during human melanoma progression (Levy et al.,
2010).
TRPM7
TRPM7, as TRPV4, is another stretch-activated Ca2+ and
Mg2+ permeable channel, which present a kinase domain at its
C-terminus and allowing its involvement both in cellular Mg2+
status and in intracellular signaling (Bates-Withers et al., 2011;
Paravicini et al., 2012). TRPM7 has been described as a regula-
tor of actomyosin contractility, cell adhesion, and directed cell
migration (Clark et al., 2006, 2008; Su et al., 2006; Prevarskaya
et al., 2011; Schwab et al., 2012). In particular TRPM7 is respon-
sible for the Ca2+ flickers at the front lamellipodia of migrating
fibroblast mediating the polarized migration toward a chemo
attractant (Wei et al., 2009). However, a role for this bifunc-
tional channel in cancer progression has been proposed only
recently: TRPM7 is critical for cell migration of different cell can-
cer models such as breast cancer, lung cancer, nasopharingeal
cancer and pancreatic ductal adrenocarcinoma (Chen et al., 2010;
Gao et al., 2011; Middelbeek et al., 2012; Rybarczyk et al., 2012;
Meng et al., 2013). Silencing TRPM7 with specific small inter-
fering RNA lead to a significant reduction in migration and
invasion capability of MDA-MB-435 via Src and p38, JNK and
ERK1/2 signaling pathway (Meng et al., 2013) as well as by reg-
ulating myosin II–based cellular tension, thereby modifying focal
adhesion number, cell–cell adhesion and polarized cell movement
(Middelbeek et al., 2012) (Table 1; Figure 1). Interestingly in lung
cancer cells A549, EGF functionally regulates TRPM7 expression
at the plasma membrane thus increasing cell migration rate (Gao
et al., 2011) while TRPM7 protein downregulation significantly
interferes with the metastatic potential of human breast cancer
in vivo (Middelbeek et al., 2012).
On the other hand TRPM7 is involved in a number of vascu-
lar disorders such as hypertension and dysfunction of endothelial
and smooth muscle cells (Yogi et al., 2011).
Opposite data have been reported for different ECs: while
TRPM7 silencing significantly impairs HMEC motility (Baldoli
and Maier, 2012), TRPM7 inhibition stimulates HUVEC to
migrate (Baldoli et al., 2013). These results further underscores
that TRPM7 serves different functions in EC of different ori-
gins. On possible explanation for this descrepancy is that HUVEC
andmicrovascular ECmight express different Mg transporters. In
particular, Baldoli and coworkers discuss the possibility that other
Mg channels vicariate TRPM7 functions in HUVEC.
TRPM8
TRPM8 expression is strongly up-regulated in numerous can-
cers such as prostate, breast, colon, lung, pancreas and skin while
it is dramatically reduced during metastasis in the androgen-
independent prostate cancer (Tsavaler et al., 2001; Henshall et al.,
2003; Yee et al., 2010). This pattern of variation in TRPM8
channel expression makes it an interesting candidate as a diag-
nostic marker for detection of cancer and as prognosis marker
for evaluating the outcome of epithelial cancers (Zhang and
Barritt, 2006). Concerning the role of this channel in migration
Gkika et al have recently propose that it could have a protec-
tive role in prostate metastatic cancer (Gkika and Prevarskaya,
2011), since recent data show that it blocks cancer cell migra-
tion in prostate cells (Yang et al., 2009b; Gkika et al., 2010;
Zhu et al., 2011; Wang et al., 2012). In particular overexpres-
sion of TRPM8 in prostate cancer cells reduces the cell motility
through the inactivation of FAK (Yang et al., 2009b) (Figure 1).
Moreover, it seems that only the presence of TRPM8 on the
plasma membrane is sufficient to reduce migration, suggesting a
basal activity of the channel possibly affecting FAK phosphoryla-
tion while TRPM8 activation by icilin, one of its agonists, further
reduced cell motility (Gkika et al., 2010). Interestingly, the well-
known prostate cancer marker, Prostate Specific Antigen (PSA)
that is secreted in the prostatic acini and is therefore in contact
with the extracellular part of TRPM8, activates the channel and
decelerates cell migration by inducing its plasmamembrane accu-
mulation (Gkika et al., 2010) (Table 1; Figure 1). Furthermore,
TRPM8 expression has a negative effect in angiogenesis as it was
recently shown in nude mice. Mice transplanted with prostate
cancer cells over-expressing TRPM8 develop tumours that are
less vascularized than control. The lower microvascular den-
sity of the TRPM8 xenografts can be explained by their lower
expression of FAK and VEGF, which is one of the most potent
angiogenic factor (Zhu et al., 2011). Taken together these three
studies suggest that TRPM8 could play a protective role in
prostate cancer progression by reducing both cell migration and
angiogenesis.
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It has to be noted that contrasting results on the role of TRPM8
in cell migration have been shown in glioblastoma, prostate can-
cer and squamous carcinoma cell lines (Wondergem et al., 2008;
Okamoto et al., 2012; Valero et al., 2012;). In particular, Nilius
and co-workers suggest that menthol (TRPM8 agonist) acceler-
ates cell migration of glioblastoma cells (Wondergem et al., 2008);
on the other hand, pharmacological agents inhibiting TRPM8
reduce cell speed of prostate cancer cells (Valero et al., 2012).
However, the authors used a pharmacological approach and no
direct data using siRNA or overexpression that would reinforce
the involvement of the channel in cell migration was provided.
The discrepancy in the results in between these different studies
can be due to several reasons: (i) the pharmacological agents used
are not the same, (ii) agonists/antagonists can involve the activa-
tion of other channels (or proteins), (iii) the cell systems were not
always the same.
It would be interesting to investigate the in vivo effects of the
activators and inhibitors of TRPM8, as well as the use of pore
mutants in addition to the wild-type channel overexpression used
in mice xenografts (Zhu et al., 2011). These experiments together
with in vitro studies could give some insight on which is the crit-
ical factor in migration during carcinogenesis: the activity of the
TRPM8 channel or the changes in conformation of the TRPM8
protein during its interaction with pharmacological agents and
its subsequent changes in protein-protein complexes? However,
the present divergence in the results is as puzzling as in the case
of TRPV1 and makes it difficult to draw conclusions concerning
the use of the channel agonists or antagonists as pharmacological
candidates in clinics.
ORAI1/STIM1 COMPLEX
Orai1 and STIM1 are components of the so-called Ca2+ release
activated currents (CRAC) channels (Yeromin et al., 2006;
Cahalan et al., 2007; Hewavitharana et al., 2007). Since they are
closely linked to TRP channel function, we will include the dis-
cussion for these proteins here. In this regard Recently, TRPC
proteins have been shown to associate with Orai1 and STIM1
in a dynamic ternary complex regulated by the occupation of
membrane receptors in several cell models, which might play an
important role in the function of TRPC proteins (Salido et al.,
2011; Cheng et al., 2013).
Reflecting the eminent importance of CRAC current following
receptor stimulation, several recent studies addressed the role of
Orai1/STIM1 in chemotactically or chemokinetically stimulated
migration with a particular focus on cell adhesion both in cancer
cells as well as in vascular endothelium. Orai1/STIM1 complex
is implicated in breast, nasopharyngeal carcinoma, cervical and
glioblastoma multiforme tumor cell migration in vitro and in a
mouse model of metastases generated by tumor xenografts (Yang
et al., 2009a; Chen et al., 2011; Motiani et al., 2013; Zhang et al.,
2013). The inhibition of store-operated Ca2+ entry (SOCE) by a
pharmacological agent, SKF96365, or by siRNA-mediated STIM1
or Orai1 silencing is able to inhibit MDA-MB- 231 cell migration
and matrigel invasion, as well as reduce the spread of xenografted
tumor cells in mice; on the other hand, reexpression of siRNA-
resistant STIM1 or Orai1 constructs rescued the invasion of the
STIM1 or Orai1 siRNA-treated cells. STIM1- andOrai1-mediated
SOCE regulates cell migration at least partly through modulating
focal adhesion turnover, which in turn facilitates cell migra-
tion of metastatic cancer cells; on the other hand blocking Ca2+
influx affects both the assembly and disassembly of focal adhe-
sions, which may impair traction force generation in migrating
cells. The defects of focal adhesion turnover and cell migration
induced by SOCE impairment can be rescued by constitutively
active forms of the small GTPases RAS and RAC, suggesting the
involvement of these regulators of focal adhesions in the mod-
ulation of cell migration by SOCE (Yang et al., 2009a) (Table 1;
Figure 1). Similar results were obtained on hepatoblastoma cell
line where STIM1 play a key role in focal adhesion turnover (Yang
et al., 2013). STIM1 is also a key player in EGF-mediated cervical
cancer and nasopharyngeal carcinoma cell migration by inhibit-
ing calpain activity and focal adhesion turnover (Chen et al.,
2011; Zhang et al., 2013); STIM1 play also a role in stimulating
angiogenesis by regulating VEGF-A release from cancer cells thus
proposing a multiple function for STIM1 in tumor biology (Chen
et al., 2011). On the other hand recently the association of Orai1
and K+ channels have been involved in cancer cell migration: SK3
channels functionally associate with the Orai1 channel in a breast
cancer MDA-MB-435s within lipid rafts. This localization of an
SK3–Orai1 complex seemed essential to control cancer cell migra-
tion and bone methastases. Interestingly, STIM1 seems not to be
involved in this effect (Chantôme et al., 2013) (Figure 1).
The role of ORAI1/STIM1 complex has been studied recently
also in EC migration and tumor vascularization. In particular it
concurs to the VEGF-mediated SOCE in HUVECs (Abdullaev
et al., 2008; Li et al., 2011). VEGF stimulation promotes STIM1
clustering which in turn activates Orai1 (Li et al., 2011).
Moreover, knock-down of Orai1 inhibits HUVECmigration, pro-
liferation and in vitro tubulogenesis subsequent to the sustained
intracellular Ca2+ elevation triggered by VEGF (Abdullaev et al.,
2008; Li et al., 2011; Beech, 2012) (Figure 1). Interestingly, it
has been recently reported that STIM1, as well as TRPC1 and
TRPC4 knockdown, reduces tube formation in both HUVECs
and EA.hy926 cells (Antigny et al., 2012). These data are of par-
ticular interest since functional interaction between Orai1 and
TRPC1 has been described as previously stated (Ong et al., 2007;
Salido et al., 2011; Cheng et al., 2013).
Notably, suppression of Orai1 expression or expression of
dominant negative mutants of Orai1 abolish SOCE in EPCs as
well as in vitro tubule formation (Li et al., 2011). Blockade of
SOCE affects EPC proliferation, migration and in vitro tubulo-
genesis induced by VEGF (Dragoni et al., 2011). Moreover, EPCs
isolated from RCC patients (RCC-EPCs) display a greater SOCE,
which correlates with the over-expression of Orai1, Stim1, and
TRPC1 as compared to control cells (EPCs from healthy patient)
(Lodola et al., 2012).
CONCLUSIONS
In the two last decades the progressive understanding of the
molecular mechanisms that regulate the establishment and pro-
gression of different tumors is leading to even more specific
and efficacious pharmacological approaches. In this picture, TRP
channels represent a very promising player since their expres-
sion and activity mark and regulate specific stages of cancer
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progression (Gkika and Prevarskaya, 2009; Prevarskaya et al.,
2011; Schwab et al., 2012; Ouadid-Ahidouch et al., 2013). On the
other hand, the downside of migration is represented by disease
conditions in which cell migration constitutes amajor pathophys-
iological element. The most prominent example is the formation
of tumor metastases. Tumor cell migration is an essential step of
the so-called metastatic cascade that leads to the spread of the dis-
ease within the body (Yamaguchi et al., 2005; Lohela and Werb,
2010).
The data presented in this review firmly proof the concept that
different members of the TRP family of channels constitute inte-
gral components of the cellular migration machinery linking in
many cases the plasma membrane (or intracellular membranes)
signals to cytoskeletal migration motor or cell adhesion proteins
functions in cancer cells. Indeed, locomotion involves lamellipo-
dial extensions at the leading edge, new attachments to stabilize
the extension, transcellular contractility, and detachment at the
rear. These processes involve a multitude of molecules such as
growth factors and their receptors, matrix metalloproteinases,
integrin, small GTPases, FAK and SRC kinases, elements of the
cytoskeleton, all of which underlie biochemical events of the
moving cells. In particular, data on TRPM7 and Orai1/STIM1
complex clearly link these channels to this dynamic process lead-
ing to directional migration (Yang et al., 2009a; Middelbeek et al.,
2012). It is also clear that the study of TRP channels in cellu-
lar migration is a young field (as denoted by the fact that the
majority of data are from the last 10 years) so that studies mecha-
nistically linking the channel role to the migration machinery are
still limited and more research is needed. On the other hand, the
scientific interest on this topic is largely increasing as pointed out
by PubMed search and we aspect the knowledge of the molecular
mechanisms responsible for TRP channels role in migration will
be largely unveiled in the next ten years.
Another issue to be considered is the wide distribution as
well as the multiplicity of cancer hallmarks controlled by a
given TRP or Orai1 protein which requires careful considera-
tion of its therapeutic potential. This problem could be overcome
by directed targeted therapies taking advantage from nano-
biomedicine: for example, nanoparticle functionalization with
peptide cyclic RGD for angiogenesis-specific targeting (Cheng
et al., 2011) together with a specific channel modulator could
be successfully employed. Another good example of such a strat-
egy is the ‘smart bomb’ for prostate cancer, which combines a
sarcolemmal and endoplasmic reticulum Ca2+-ATPase (SERCA)
inhibitor thapsigargin (which induces apoptosis through the acti-
vation of ER stress and Ca2+ entry pathways) with a targeting
peptide that is a substrate of the serine/protease prostate-specific
antigen (PSA) (Denmeade and Isaacs, 2005).
The wide expression of TRP channels has also to be taken in
account regarding vascular endothelium. In this regard when con-
sidering TRPV4 potential role in tumor vascularization (Fiorio
Pla et al., 2012b) it’s important to notice that TRPV4 is ubiq-
uitary in healthy vascular endothelium and plays a physiological
role both in large arteries and microvessels: these relevant activi-
ties require careful consideration of its therapeutic potential. On
the other hand, an overexpression on TEC could be exploited
for a tumor targeted therapy based on lower inhibiting doses of
TRPV4 antagonists which could selectively affect TEC and not
normal EC.
Moreover ubiquitous expression of the channels could be used
as a positive feature, due to the redundancy of the signaling path-
ways which regulates the different hallmarks of cancer: in other
words, the use of specific channels to selective co-target different
key steps of carcinogenesis beside tumor vascularization, could
result in more effective and long lasting therapies. For exam-
ple, TRPC6 channels targeting could affect VEGF release from
tumor cells as well as EC migration and tumor vascularization
(Hamdollah Zadeh et al., 2008; Ge et al., 2009; Chigurupati et al.,
2010).
In addition as it was described above for some channels
(TRPV1 and TRPM8) pharmacological action has not always
the same result with siRNA and/or overexpression approaches
due to broad action on several cellular components. There is
therefore a real need for detailed studies in vivo in order to
test which are the most effective and suitable molecules to tar-
get in therapeutics. Another reason for the possible differences
in the cellular responses observed in different tumors could be
due to some peculiar features of these channels in certain cel-
lular environments. It is now well described that TRP channel
can interact in specific microdomains giving rise to different sig-
nal transduction pathways and cellular signals. In this regard
an example is given by TRPC6: when associated with VEGF
receptor TRPC6 may function as downstream player and acti-
vate EC migration (Chigurupati et al., 2010); on the other hand
when localized in proximity with TRPC5, TRPC6-TRPC5 cas-
cade results in attenuation of EC migration (Chaudhuri et al.,
2008). On the other hand TRP and ORAI1 channels functionally
interact with other family of channels: a nice example is TRPC1
which is functionally related to ClC-3 in caveolar lipid rafts of
glioma cells to promote EGF-induced chemotaxis (Cuddapah
et al., 2013). Similarly ORAI1 interacts with K+ channels in breast
cancer (Chantôme et al., 2013). Differences in channels com-
plexes and/or microdomain localization could therefore account
for different cellular effect in tumors.
In conclusion we expect that the more detailed understand-
ing together with a more integrative view on TRP channels in cell
migration, as well as careful studies using appropriate in vivo and
in vitro models, will facilitate the advances in this exiting field of
cellular physiopathology
ACKNOWLEDGMENTS
We thank Daniele Avanzato (PhD student in Complex Systems in
Life Sciences, University of Torino) for art graphics.
REFERENCES
Abdullaev, I. F., Bisaillon, J. M., Potier, M., Gonzalez, J. C., Motiani,
R. K., and Trebak, M. (2008). Stim1 and Orai1 mediate CRAC cur-
rents and store-operated calcium entry important for endothelial cell
proliferation. Circ. Res. 103, 1289–1299. doi: 10.1161/01.RES.0000338496.
95579.56
Ambudkar, I. S., and Ong, H. L. (2007). Organization and function of TRPC
channelosomes. Pflugers Arch. 455, 187–200. doi: 10.1007/s00424-007-0252-0
Antigny, F., Girardin, N., and Frieden, M. (2012). Transient receptor potential
canonical channels are required for in vitro endothelial tube formation. J. Biol.
Chem. 287, 5917–5927. doi: 10.1074/jbc.M111.295733
www.frontiersin.org November 2013 | Volume 4 | Article 311 | 9
Fiorio Pla and Gkika TRPs in tumor cell migration
Aydar, E., Yeo, S., Djamgoz, M., and Palmer, C. (2009). Abnormal expression, local-
ization and interaction of canonical transient receptor potential ion channels in
human breast cancer cell lines and tissues: a potential target for breast cancer
diagnosis and therapy. Cancer Cell Int. 9, 23. doi: 10.1186/1475-2867-9-23
Baldoli, E., Castiglioni, S., and Maier, J. A. M. (2013). Regulation and function of
TRPM7 in human endothelial cells: TRPM7 as a potential novel regulator of
endothelial function. PLoS ONE 8:e59891. doi: 10.1371/journal.pone.0059891
Baldoli, E., andMaier, J. A. M. (2012). Silencing TRPM7mimics the effects of mag-
nesium deficiency in human microvascular endothelial cells. Angiogenesis 15,
47–57. doi: 10.1007/s10456-011-9242-0
Bates-Withers, C., Sah, R., and Clapham, D. E. (2011). TRPM7, the Mg(2+) inhib-
ited channel and kinase. Adv. Exp. Med. Biol. 704, 173–183. doi: 10.1007/978-
94-007-0265-3_9
Beech, D. J. (2012). Orai1 calcium channels in the vasculature. Pflugers Arch. 463,
635–647. doi: 10.1007/s00424-012-1090-2
Bernaldo de Quirós, S., Merlo, A., Secades, P., Zambrano, I., de Santa María, I. S.,
Ugidos, N., et al. (2013). Identification of TRPC6 as a possible candidate target
gene within an amplicon at 11q21-q22.2 for migratory capacity in head and
neck squamous cell carcinomas. BMC Cancer 13:116. doi: 10.1186/1471-2407-
13-116
Blázquez, C., González-Feria, L., Alvarez, L., Haro, A., Casanova, M. L., and
Guzmán, M. (2004). Cannabinoids inhibit the vascular endothelial growth
factor pathway in gliomas. Cancer Res. 64, 5617–5623. doi: 10.1158/0008-
5472.CAN-03-3927
Bödding, M. (2007). TRP proteins and cancer. Cell. Signal. 19, 617–624. doi:
10.1016/j.cellsig.2006.08.012
Bomben, V. C., and Sontheimer, H. W. (2008). Inhibition of transient receptor
potential canonical channels impairs cytokinesis in human malignant gliomas.
Cell Prolif. 41, 98–121. doi: 10.1111/j.1365-2184.2007.00504.x
Bomben, V. C., Turner, K. L., Barclay, T.-T. C., and Sontheimer, H. (2011).
Transient receptor potential canonical channels are essential for chemotactic
migration of human malignant gliomas. J. Cell. Physiol. 226, 1879–1888. doi:
10.1002/jcp.22518
Bussolati, B., Grange, C., and Camussi, G. (2011). Tumor exploits alternative
strategies to achieve vascularization. FASEB J. 25, 2874–2882. doi: 10.1096/fj.10-
180323
Cahalan, M. D., Zhang, S. L., Yeromin, A. V., Ohlsen, K., Roos, J., and Stauderman,
K. A. (2007). Molecular basis of the CRAC channel. Cell Calcium 42, 133–144.
doi: 10.1016/j.ceca.2007.03.002
Caprodossi, S., Amantini, C., Nabissi, M., Morelli, M. B., Farfariello, V., Santoni,
M., et al. (2011). Capsaicin promotes a more aggressive gene expression pheno-
type and invasiveness in null-TRPV1 urothelial cancer cells. Carcinogenesis 32,
686–694. doi: 10.1093/carcin/bgr025
Caprodossi, S., Lucciarini, R., Amantini, C., Nabissi, M., Canesin, G., Ballarini,
P., et al. (2008). Transient receptor potential vanilloid type 2 (TRPV2)
expression in normal urothelium and in urothelial carcinoma of human
bladder: correlation with the pathologic stage. Eur. Urol. 54, 612–620. doi:
10.1016/j.eururo.2007.10.016
Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature 438,
932–936. doi: 10.1038/nature04478
Chantôme, A., Potier-Cartereau, M., Clarysse, L., Fromont, G., Marionneau-
Lambot, S., Guéguinou, M., et al. (2013). Pivotal role of the lipid raft SK3-Orai1
complex in human cancer cell migration and bone metastases. Cancer Res. 73,
4852–4861. doi: 10.1158/0008-5472.CAN-12-4572
Chaudhuri, P., Colles, S. M., Bhat, M., Van Wagoner, D. R., Birnbaumer, L.,
and Graham, L. M. (2008). Elucidation of a TRPC6-TRPC5 channel cascade
that restricts endothelial cell movement. Mol. Biol. Cell 19, 3203–3211. doi:
10.1091/mbc.E07-08-0765
Cheng, H.-W., James, A. F., Foster, R. R., Hancox, J. C., and Bates, D. O.
(2006). VEGF activates receptor-operated cation channels in human microvas-
cular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26, 1768–1776. doi:
10.1161/01.ATV.0000231518.86795.0f
Cheng, J., Gu, Y.-J., Wang, Y., Cheng, S. H., and Wong, W.-T. (2011).
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug effi-
cacy and biocompatibility in zebrafish embryos. Int. J. Nanomed. 6, 2007–2021.
doi: 10.2147/IJN.S20145
Cheng, K. T., Ong, H. L., Liu, X., and Ambudkar, I. S. (2013). Contribution and
regulation of TRPC channels in store-operated Ca(2+) entry. Curr. Top. Membr.
71, 149–179. doi: 10.1016/B978-0-12-407870-3.00007-X
Chen, J.-P., Luan, Y., You, C.-X., Chen, X.-H., Luo, R.-C., and Li, R. (2010). TRPM7
regulates the migration of human nasopharyngeal carcinoma cell by mediating
Ca(2+) influx. Cell Calcium 47, 425–432. doi: 10.1016/j.ceca.2010.03.003
Chen, Y.-F., Chiu, W.-T., Chen, Y.-T., Lin, P.-Y., Huang, H.-J., Chou, C.-Y.,
et al. (2011). Calcium store sensor stromal-interaction molecule 1-dependent
signaling plays an important role in cervical cancer growth, migration,
and angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 108, 15225–15230. doi:
10.1073/pnas.1103315108
Chigurupati, S., Venkataraman, R., Barrera, D., Naganathan, A., Madan, M.,
Paul, L.,.et al. (2010). Receptor channel TRPC6 is a key mediator of notch-
driven glioblastoma growth and invasiveness. Cancer Res. 70, 418–427. doi:
10.1158/0008-5472.CAN-09-2654
Clark, K., Langeslag, M., van Leeuwen, B., Ran, L., Ryazanov, A. G., Figdor, C.
G., et al. (2006). TRPM7, a novel regulator of actomyosin contractility and cell
adhesion. EMBO J. 25, 290–301. doi: 10.1038/sj.emboj.7600931
Clark, K., Middelbeek, J., and van Leeuwen, F. N. (2008). Interplay between TRP
channels and the cytoskeleton in health and disease. Eur. J. Cell Biol. 87,
631–640. doi: 10.1016/j.ejcb.2008.01.009
Cuddapah, V. A., Turner, K. L., and Sontheimer, H. (2013). Calcium entry via
TRPC1 channels activates chloride currents in human glioma cells.Cell Calcium
53, 187–194. doi: 10.1016/j.ceca.2012.11.013
Denmeade, S. R., and Isaacs, J. T. (2005). The SERCA pump as a therapeutic target:
making a “smart bomb” for prostate cancer. Cancer Biol. Ther. 4, 14–22. doi:
10.4161/cbt.4.1.1505
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino,
S., et al. (2011). Effects of cannabinoids and cannabinoid-enriched cannabis
extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J.
Pharmacol. 163, 1479–1494. doi: 10.1111/j.1476-5381.2010.01166.x
Dragoni, S., Laforenza, U., Bonetti, E., Lodola, F., Bottino, C., Berra-Romani, R.,
et al. (2011). Vascular endothelial growth factor stimulates endothelial colony
forming cells proliferation and tubulogenesis by inducing oscillations in intra-
cellular Ca2+ concentration. Stem Cells 29, 1898–1907. doi: 10.1002/stem.734
Duncan, L. M., Deeds, J., Hunter, J., Shao, J., Holmgren, L. M., Woolf, E. A., et al.
(1998). Down-regulation of the novel gene melastatin correlates with potential
for melanoma metastasis. Cancer Res. 58, 1515–1520.
El Boustany, C., Bidaux, G., Enfissi, A., Delcourt, P., Prevarskaya, N., and Capiod,
T. (2008). Capacitative calcium entry and transient receptor potential canon-
ical 6 expression control human hepatoma cell proliferation. Hepatology 47,
2068–2077. doi: 10.1002/hep.22263
Everaerts, W., Nilius, B., and Owsianik, G. (2010). The vanilloid transient receptor
potential channel TRPV4: from structure to disease. Prog. Biophys. Mol. Biol.
103, 2–17. doi: 10.1016/j.pbiomolbio.2009.10.002
Fabian, A., Fortmann, T., Dieterich, P., Riethmüller, C., Schön, P., Mally, S., et al.
(2008). TRPC1 channels regulate directionality of migrating cells. Pflugers Arch.
457, 475–484. doi: 10.1007/s00424-008-0515-4
Fang, D., and Setaluri, V. (2000). Expression and Up-regulation of alterna-
tively spliced transcripts of melastatin, a melanoma metastasis-related gene,
in human melanoma cells. Biochem. Biophys. Res. Commun. 279, 53–61. doi:
10.1006/bbrc.2000.3894
Fiorio Pla, A., Avanzato, D., Munaron, L., and Ambudkar, I. S. (2012a). Ion chan-
nels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as
molecular targets. Am. J. Physiol. Cell Physiol. 302, C9–C15. doi: 10.1152/ajp-
cell.00280.2011
Fiorio Pla, A., Ong, H. L., Cheng, K. T., Brossa, A., Bussolati, B., Lockwich,
T., et al. (2012b). TRPV4 mediates tumor-derived endothelial cell migration
via arachidonic acid-activated actin remodeling. Oncogene 31, 200–212. doi:
10.1038/onc.2011.231
Gao, H., Chen, X., Du, X., Guan, B., Liu, Y., and Zhang, H. (2011). EGF enhances
the migration of cancer cells by up-regulation of TRPM7. Cell Calcium 50,
559–568. doi: 10.1016/j.ceca.2011.09.003
Ge, R., Tai, Y., Sun, Y., Zhou, K., Yang, S., Cheng, T., et al. (2009). Critical role of
TRPC6 channels in VEGF-mediated angiogenesis. Cancer Lett. 283, 43–51. doi:
10.1016/j.canlet.2009.03.023
Gkika, D., Flourakis, M., Lemonnier, L., and Prevarskaya, N. (2010). PSA reduces
prostate cancer cell motility by stimulating TRPM8 activity and plasma mem-
brane expression. Oncogene 29, 4611–4616. doi: 10.1038/onc.2010.210
Gkika, D., and Prevarskaya, N. (2009). Molecular mechanisms of TRP regulation
in tumor growth and metastasis. Biochim. Biophys. Acta 1793, 953–958. doi:
10.1016/j.bbamcr.2008.11.010
Frontiers in Physiology | Membrane Physiology and Membrane Biophysics November 2013 | Volume 4 | Article 311 | 10
Fiorio Pla and Gkika TRPs in tumor cell migration
Gkika, D., and Prevarskaya, N. (2011). TRP channels in prostate cancer: the good,
the bad and the ugly. Asian J. Androl. 13, 673–676. doi: 10.1038/aja.2011.18
Guilbert, A., Dhennin-Duthille, I., Hiani, Y., El, Haren, N., Khorsi, H., Ouadid-
Ahidouch, H., et al. (2008). Expression of TRPC6 channels in human epithelial
breast cancer cells. BMC Cancer 8:125. doi: 10.1186/1471-2407-8-125
Hamdollah Zadeh, M. A., Glass, C. A., Magnussen, A., Hancox, J. C., and Bates, D.
O. (2008). VEGF-mediated elevated intracellular calcium and angiogenesis in
human microvascular endothelial cells in vitro are inhibited by dominant nega-
tive TRPC6. Microcirculation 15, 605–614. doi: 10.1080/10739680802220323
Hao, F., Tan, M., Xu, X., Han, J., Miller, D. D., Tigyi, G., et al. (2007).
Lysophosphatidic acid induces prostate cancer PC3 cell migration via activa-
tion of LPA(1), p42 and p38alpha. Biochim. Biophys. Acta 1771, 883–892. doi:
10.1016/j.bbalip.2007.04.010
Hartmannsgruber, V., Heyken, W.-T., Kacik, M., Kaistha, A., Grgic, I., Harteneck,
C., et al. (2007). Arterial response to shear stress critically depends on endothe-
lial TRPV4 expression. PLoS ONE 2:e827. doi: 10.1371/journal.pone.0000827
Hewavitharana, T., Deng, X., Soboloff, J., and Gill, D. L. (2007). Role of STIM and
Orai proteins in the store-operated calcium signaling pathway. Cell Calcium 42,
173–182. doi: 10.1016/j.ceca.2007.03.009
Henshall, S. M., Afar, D. E. H., Hiller, J., Horvath, L. G., Quinn, D. I., Rasiah, K.
K., et al. (2003). Survival analysis of genome-wide gene expression profiles of
prostate cancers identifies new prognostic targets of disease relapse. Cancer Res.
63, 4196–4203.
Hisatsune, C., Kuroda, Y., Nakamura, K., Inoue, T., Nakamura, T., Michikawa, T.,
et al. (2004). Regulation of TRPC6 channel activity by tyrosine phosphoryla-
tion. J. Biol. Chem. 279, 18887–18894. doi: 10.1074/jbc.M311274200
Kini, V., Chavez, A., and Mehta, D. (2010). A new role for PTEN in regulat-
ing transient receptor potential canonical channel 6-mediated Ca2+ entry,
endothelial permeability, and angiogenesis. J. Biol. Chem. 285, 33082–33091.
doi: 10.1074/jbc.M110.142034
Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo,
H., et al. (1993). Adrenomedullin: a novel hypotensive peptide isolated from
human pheochromocytoma. Biochem. Biophys. Res. Commun. 192, 553–560.
doi: 10.1006/bbrc.1993.1451
Kuang, C., Yu, Y., Wang, K., Qian, D., Den, M., and Huang, L. (2012). Knockdown
of transient receptor potential canonical-1 reduces the proliferation and
migration of endothelial progenitor cells. Stem Cells Dev. 21, 487–496. doi:
10.1089/scd.2011.0027
Levy, C., Khaled, M., Iliopoulos, D., Janas, M. M., Schubert, S., Pinner, S.,
et al. (2010). Intronic miR-211 assumes the tumor suppressive function of
its host gene in melanoma. Mol. Cell 40, 841–849. doi: 10.1016/j.molcel.2010.
11.020
Li, J., Cubbon, R. M., Wilson, L. A., Amer, M. S., McKeown, L., Hou, B.,
et al. (2011). Orai1 and CRAC channel dependence of VEGF-activated
Ca2+ entry and endothelial tube formation. Circ. Res. 108, 1190–1198. doi:
10.1161/CIRCRESAHA.111.243352
Lodola, F., Laforenza, U., Bonetti, E., Lim, D., Dragoni, S., Bottino, C., et al. (2012).
Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in
endothelial progenitor cells isolated from tumoral patients. PLoS ONE 7:e42541.
doi: 10.1371/journal.pone.0042541
Lohela, M., and Werb, Z. (2010). Intravital imaging of stromal cell dynam-
ics in tumors. Curr. Opin. Genet. Dev. 20, 72–78. doi: 10.1016/j.gde.
2009.10.011
Matthews, B. D., Thodeti, C. K., Tytell, J. D., Mammoto, A., Overby, D. R., and
Ingber, D. E. (2010). Ultra-rapid activation of TRPV4 ion channels by mechani-
cal forces applied to cell surface beta1 integrins. Integr. Biol. (Camb). 2, 435–442.
doi: 10.1039/c0ib00034e
Ma, X., Cao, J., Luo, J., Nilius, B., Huang, Y., Ambudkar, I. S., et al.
(2010). Depletion of intracellular Ca2+ stores stimulates the translocation
of vanilloid transient receptor potential 4-c1 heteromeric channels to the
plasma membrane. Arterioscler. Thromb. Vasc. Biol. 30, 2249–2255. doi:
10.1161/ATVBAHA.110.212084
Ma, X., Cheng, K.-T., Wong, C.-O., O’Neil, R. G., Birnbaumer, L., Ambudkar,
I. S., et al. (2011). Heteromeric TRPV4-C1 channels contribute to store-
operated Ca(2+) entry in vascular endothelial cells. Cell Calcium 50,
502–509. doi: 10.1016/j.ceca.2011.08.006
Meng, X., Cai, C., Wu, J., Cai, S., Ye, C., Chen, H., et al. (2013). TRPM7 mediates
breast cancer cell migration and invasion through the MAPK pathway. Cancer
Lett. 333, 96–102. doi: 10.1016/j.canlet.2013.01.031
Middelbeek, J., Kuipers, A. J., Henneman, L., Visser, D., Eidhof, I., van Horssen, R.,
et al. (2012). TRPM7 is required for breast tumor cell metastasis. Cancer Res. 72,
4250–4261. doi: 10.1158/0008-5472.CAN-11-3863
Moffett, H. F., and Novina, C. D. (2007). A small RNA makes a Bic difference.
Genome Biol. 8:221. doi: 10.1186/gb-2007-8-7-221
Monet, M., Gkika, D., Lehen’kyi, V., Pourtier, A., Vanden Abeele, F., Bidaux,
G., et al. (2009). Lysophospholipids stimulate prostate cancer cell migration
via TRPV2 channel activation. Biochim. Biophys. Acta 1793, 528–539. doi:
10.1016/j.bbamcr.2009.01.003
Monet, M., Lehen’kyi, V., Gackiere, F., Firlej, V., Vandenberghe, M., Roudbaraki,
M., et al. (2010). Role of cationic channel TRPV2 in promoting prostate cancer
migration and progression to androgen resistance. Cancer Res. 70, 1225–1235.
doi: 10.1158/0008-5472.CAN-09-2205
Monteith, G. R., Davis, F. M., and Roberts-Thomson, S. J. (2012). Calcium chan-
nels and pumps in cancer: changes and consequences. J. Biol. Chem. 287,
31666–31673. doi: 10.1074/jbc.R112.343061
Montell, C. (2011). The history of TRP channels, a commentary and reflection.
Pflugers Arch. 461, 499–506. doi: 10.1007/s00424-010-0920-3
Motiani, R. K., Hyzinski-García, M. C., Zhang, X., Henkel, M. M., Abdullaev, I. F.,
Kuo, Y.-H., et al. (2013). STIM1 and Orai1 mediate CRAC channel activity and
are essential for human glioblastoma invasion. Pflugers Arch. 465, 1249–1260.
doi: 10.1007/s00424-013-1254-8
Munaron, L., Genova, T., Avanzato, D., Antoniotti, S., and Fiorio Pla, A.
(2013). Targeting calcium channels to block tumor vascularization. Recent Pat.
Anticancer. Drug Discov. 8, 27–37. doi: 10.2174/1574892811308010027
Nakamura, M., Han, B., Nunobiki, O., and Kakudo, K. (2006). Adrenomedullin: a
tumor progression factor via angiogenic control. Curr. Cancer Drug Targets 6,
635–643. doi: 10.2174/156800906778742442
Nikitenko, L. L., Fox, S. B., Kehoe, S., Rees, M. C. P., and Bicknell, R.
(2006). Adrenomedullin and tumour angiogenesis. Br. J. Cancer 94, 1–7. doi:
10.1038/sj.bjc.6602832
Nilius, B., and Owsianik, G. (2011). The transient receptor potential family of ion
channels. Genome Biol. 12, 218. doi: 10.1186/gb-2011-12-3-218
Nilius, B., Owsianik, G., Voets, T., and Peters, J. A. (2007). Transient receptor poten-
tial cation channels in disease. Physiol. Rev. 87, 165–217. doi: 10.1152/phys-
rev.00021.2006
Okamoto, Y., Ohkubo, T., Ikebe, T., and Yamazaki, J. (2012). Blockade of TRPM8
activity reduces the invasion potential of oral squamous carcinoma cell lines.
Int. J. Oncol. 40, 1431–1440. doi: 10.3892/ijo.2012.1340
Ong, H. L., Cheng, K. T., Liu, X., Bandyopadhyay, B. C., Paria, B. C., Soboloff,
J., et al. (2007). Dynamic assembly of TRPC1-STIM1-Orai1 ternary complex
is involved in store-operated calcium influx. Evidence for similarities in store-
operated and calcium release-activated calcium channel components. J. Biol.
Chem. 282, 9105–9116. doi: 10.1074/jbc.M608942200
Ouadid-Ahidouch, H., Dhennin-Duthille, I., Gautier, M., Sevestre, H., and
Ahidouch, A. (2013). TRP channels: diagnostic markers and thera-
peutic targets for breast cancer. Trends Mol. Med. 19, 117–124. doi:
10.1016/j.molmed.2012.11.004
Oulidi, A., Bokhobza, A., Gkika, D., Vanden Abeele, F., Lehen’kyi, V., Ouafik, L.,
et al. (2013). TRPV2 Mediates adrenomedullin stimulation of prostate and
urothelial cancer cell adhesion, migration and invasion. PLoS ONE 8:e64885.
doi: 10.1371/journal.pone.0064885
Paravicini, T. M., Chubanov, V., and Gudermann, T. (2012). TRPM7: a unique
channel involved in magnesium homeostasis. Int. J. Biochem. Cell Biol. 44,
1381–1384. doi: 10.1016/j.biocel.2012.05.010
Portella, G., Laezza, C., Laccetti, P., De Petrocellis, L., Di Marzo, V., and
Bifulco, M. (2003). Inhibitory effects of cannabinoid CB1 receptor stimula-
tion on tumor growth and metastatic spreading: actions on signals involved
in angiogenesis and metastasis. FASEB J. 17, 1771–1773. doi: 10.1096/fj.02-
1129fje
Prevarskaya, N., Skryma, R., and Shuba, Y. (2011). Calcium in tumour metastasis:
new roles for known actors.Nat. Rev. Cancer 11, 609–618. doi: 10.1038/nrc3105
Raj, G. V., Sekula, J. A., Guo, R., Madden, J. F., and Daaka, Y. (2004).
Lysophosphatidic acid promotes survival of androgen-insensitive prostate
cancer PC3 cells via activation of NF-kappaB. Prostate 61, 105–113. doi:
10.1002/pros.20083
Ramer, R., and Hinz, B. (2008). Inhibition of cancer cell invasion by cannabinoids
via increased expression of tissue inhibitor of matrix metalloproteinases-1.
J. Natl. Cancer Inst. 100, 59–69. doi: 10.1093/jnci/djm268
www.frontiersin.org November 2013 | Volume 4 | Article 311 | 11
Fiorio Pla and Gkika TRPs in tumor cell migration
Ramer, R., Merkord, J., Rohde, H., andHinz, B. (2010). Cannabidiol inhibits cancer
cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1.
Biochem. Pharmacol. 79, 955–966. doi: 10.1016/j.bcp.2009.11.007
Ramsey, I. S., Delling, M., and Clapham, D. E. (2006). An intro-
duction to TRP channels. Annu. Rev. Physiol. 68, 619–647. doi:
10.1146/annurev.physiol.68.040204.100431
Roderick, H. L., and Cook, S. J. (2008). Ca2+ signalling checkpoints in cancer:
remodelling Ca2+ for cancer cell proliferation and survival. Nat. Rev. Cancer
8, 361–375. doi: 10.1038/nrc2374
Rybarczyk, P., Gautier, M., Hague, F., Dhennin-Duthille, I., Chatelain, D., Kerr-
Conte, J., et al. (2012). Transient receptor potential melastatin-related 7 channel
is overexpressed in human pancreatic ductal adenocarcinomas and regulates
human pancreatic cancer cell migration. Int. J. Cancer 131, E851–E861. doi:
10.1002/ijc.27487
Salido, G. M., Jardín, I., and Rosado, J. A. (2011). The TRPC ion channels:
association with Orai1 and STIM1 proteins and participation in capacitative
and non-capacitative calcium entry. Adv. Exp. Med. Biol. 704, 413–433. doi:
10.1007/978-94-007-0265-3_23
Schwab, A., Fabian, A., Hanley, P. J., and Stock, C. (2012). Role of ion channels and
transporters in cell migration. Physiol. Rev. 92, 1865–1913. doi: 10.1152/phys-
rev.00018.2011
Song, J., Wang, Y., Li, X., Shen, Y., Yin, M., Guo, Y., et al. (2013). Critical role of
TRPC6 channels in the development of human renal cell carcinoma. Mol. Biol.
Rep. 40, 5115–5122. doi: 10.1007/s11033-013-2613-4
Su, L.-T., Agapito, M. A., Li, M., Simonson, W. T. N., Huttenlocher, A.,
Habas, R., et al. (2006). TRPM7 regulates cell adhesion by controlling the
calcium-dependent protease calpain. J. Biol. Chem. 281, 11260–11270. doi:
10.1074/jbc.M512885200
Thebault, S., Flourakis, M., Vanoverberghe, K., Vandermoere, F., Roudbaraki, M.,
Lehen’kyi, V., et al. (2006). Differential role of transient receptor potential chan-
nels in Ca2+ entry and proliferation of prostate cancer epithelial cells. Cancer
Res. 66, 2038–2047. doi: 10.1158/0008-5472.CAN-05-0376
Thodeti, C. K., Matthews, B., Ravi, A., Mammoto, A., Ghosh, K., Bracha, A. L., et al.
(2009). TRPV4 channels mediate cyclic strain-induced endothelial cell reori-
entation through integrin-to-integrin signaling. Circ. Res. 104, 1123–1130. doi:
10.1161/CIRCRESAHA.108.192930
Troidl, C., Troidl, K., Schierling, W., Cai, W.-J., Nef, H., Möllmann, H., et al.
(2009). Trpv4 induces collateral vessel growth during regeneration of the arte-
rial circulation. J. Cell. Mol. Med. 13, 2613–2621. doi: 10.1111/j.1582-4934.2008.
00579.x
Tsavaler, L., Shapero, M. H., Morkowski, S., and Laus, R. (2001). Trp-p8, a novel
prostate-specific gene, is up-regulated in prostate cancer and other malignancies
and shares high homology with transient receptor potential calcium channel
proteins. Cancer Res. 61, 3760–3769.
Valero, M. L., Mello de Queiroz, F., Stühmer, W., Viana, F., and Pardo, L. A.
(2012). TRPM8 ion channels differentially modulate proliferation and cell cycle
distribution of normal and cancer prostate cells. PLoS ONE 7:e51825. doi:
10.1371/journal.pone.0051825
Venkatachalam, K., and Montell, C. (2007). TRP channels. Annu. Rev. Biochem. 76,
387–417. doi: 10.1146/annurev.biochem.75.103004.142819
Vriens, J., Watanabe, H., Janssens, A., Droogmans, G., Voets, T., and Nilius, B.
(2004). Cell swelling, heat, and chemical agonists use distinct pathways for
the activation of the cation channel TRPV4. Proc. Natl. Acad. Sci. U.S.A. 101,
396–401. doi: 10.1073/pnas.0303329101
Wang, G. X., and Poo, M.-M. (2005). Requirement of TRPC channels in netrin-1-
induced chemotropic turning of nerve growth cones. Nature 434, 898–904. doi:
10.1038/nature03478
Wang, Y., Wang, X., Yang, Z., Zhu, G., Chen, D., and Meng, Z. (2012). Menthol
inhibits the proliferation and motility of prostate cancer DU145 cells. Pathol.
Oncol. Res. 18, 903–910. doi: 10.1007/s12253-012-9520-1
Waning, J., Vriens, J., Owsianik, G., Stüwe, L., Mally, S., Fabian, A., et al. (2007).
A novel function of capsaicin-sensitive TRPV1 channels: involvement in cell
migration. Cell Calcium 42, 17–25. doi: 10.1016/j.ceca.2006.11.005
Wei, C., Wang, X., Chen, M., Ouyang, K., Song, L.-S., and Cheng, H.
(2009). Calcium flickers steer cell migration. Nature 457, 901–905. doi:
10.1038/nature07577
Wondergem, R., Ecay, T. W., Mahieu, F., Owsianik, G., and Nilius, B. (2008).
HGF/SF and menthol increase human glioblastoma cell calcium and migra-
tion. Biochem. Biophys. Res. Commun. 372, 210–215. doi: 10.1016/j.bbrc.2008.
05.032
Yamaguchi, H., Wyckoff, J., and Condeelis, J. (2005). Cell migration in tumors.
Curr. Opin. Cell Biol. 17, 559–564. doi: 10.1016/j.ceb.2005.08.002
Yang, N., Tang, Y., Wang, F., Zhang, H., Xu, D., Shen, Y., et al. (2013). Blockade
of store-operated Ca(2+) entry inhibits hepatocarcinoma cell migration and
invasion by regulating focal adhesion turnover. Cancer Lett. 330, 163–169. doi:
10.1016/j.canlet.2012.11.040
Yang, S., Zhang, J. J., and Huang, X.-Y. (2009a). Orai1 and STIM1 are critical
for breast tumor cell migration and metastasis. Cancer Cell 15, 124–134. doi:
10.1016/j.ccr.2008.12.019
Yang, Z.-H., Wang, X.-H., Wang, H.-P., and Hu, L.-Q. (2009b). Effects of TRPM8
on the proliferation and motility of prostate cancer PC-3 cells. Asian J. Androl.
11, 157–165. doi: 10.1038/aja.2009.1
Yee, N. S., Zhou, W., and Lee, M. (2010). Transient receptor potential chan-
nel TRPM8 is over-expressed and required for cellular proliferation in pan-
creatic adenocarcinoma. Cancer Lett. 297, 49–55. doi: 10.1016/j.canlet.2010.
04.023
Yeromin, A. V., Zhang, S. L., Jiang, W., Yu, Y., Safrina, O., and Cahalan, M. D.
(2006). Molecular identification of the CRAC channel by altered ion selectivity
in a mutant of Orai. Nature 443, 226–229. doi: 10.1038/nature05108
Yogi, A., Callera, G. E., Antunes, T. T., Tostes, R. C., and Touyz, R. M. (2011).
Transient receptor potential melastatin 7 (TRPM7) cation channels, mag-
nesium and the vascular system in hypertension. Circ. J. 75, 237–245. doi:
10.1253/circj.CJ-10-1021
Yue, D., Wang, Y., Xiao, J.-Y., Wang, P., and Ren, C.-S. (2009). Expression of TRPC6
in benign and malignant human prostate tissues. Asian J. Androl. 11, 541–547.
doi: 10.1038/aja.2009.53
Yu, P., Gu, S., Bu, J., and Du, J. (2010). TRPC1 is essential for in vivo angiogenesis
in zebrafish. Circ. Res. 106, 1221–1232. doi: 10.1161/CIRCRESAHA.109.207670
Zhang, H., Zhou, L., Shi, W., Song, N., Yu, K., and Gu, Y. (2012). A mechanism
underlying the effects of polyunsaturated fatty acids on breast cancer. Int. J. Mol.
Med. 30, 487–494. doi: 10.3892/ijmm.2012.1022
Zhang, J., Wei, J., Kanada, M., Yan, L., Zhang, Z., Watanabe, H., et al. (2013).
Inhibition of store-operated Ca2+ entry suppresses EGF-inducedmigration and
eliminates extravasation from vasculature in nasopharyngeal carcinoma cell.
Cancer Lett. 336, 390–397. doi: 10.1016/j.canlet.2013.03.026
Zhang, L., and Barritt, G. J. (2006). TRPM8 in prostate cancer cells: a potential diag-
nostic and prognostic marker with a secretory function. Endocr. Relat. Cancer
13, 27–38. doi: 10.1677/erc.1.01093
Zhu, G., Wang, X., Yang, Z., Cao, H., Meng, Z., Wang, Y., et al. (2011). Effects
of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells
in vivo. Oncol. Lett. 2, 1213–1217. doi: 10.3892/ol.2011.410
Zudaire, E., Martínez, A., and Cuttitta, F. (2003). Adrenomedullin and cancer.
Regul. Pept. 112, 175–183. doi: 10.1016/S0167-0115(03)00037-5
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 04 July 2013; accepted: 11 October 2013; published online: 05 November
2013.
Citation: Fiorio Pla A and Gkika D (2013) Emerging role of TRP channels in
cell migration: from tumor vascularization to metastasis. Front. Physiol. 4:311. doi:
10.3389/fphys.2013.00311
This article was submitted to Membrane Physiology and Membrane Biophysics, a
section of the journal Frontiers in Physiology.
Copyright © 2013 Fiorio Pla and Gkika. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Physiology | Membrane Physiology and Membrane Biophysics November 2013 | Volume 4 | Article 311 | 12
